NCT05321316 Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
| NCT ID | NCT05321316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | Urothelial Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-05-31 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-05-31 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years old, male or female; 2. Heart function is normal; 3. Normal heart function; 4. Estimated survival ≥12 weeks; 5. Good follow-up compliance; 6. presence of at least one measurable target lesion according to RECIST1.1 criteria; 7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test; 8. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging; 9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent. Exclusion Criteria: 1. Serious abnormality of liver, kidney and blood; 2. Pregnant patients; 3. Pregnant and lactation women; 3\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05321316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Urothelial Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05321316 currently recruiting?
Yes, NCT05321316 is actively recruiting participants. Contact the research team at pekyz@163.com for enrollment information.
Where is the NCT05321316 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05321316 clinical trial?
NCT05321316 is sponsored by Peking University Cancer Hospital & Institute. The trial plans to enroll 20 participants.